Camille Maringe
@camaringe
Followers
125
Following
117
Media
6
Statuses
77
Statistician and cancer epidemiologist part of the Inequalities in Cancer Outcomes Network @icon_lshtm at the London School of Hygiene and Tropical Medicine
London
Joined May 2020
RT @ethna7: A really important concept here - the intersectionality in inequity - a close relation to the nursing perspective of personalis….
0
3
0
RT @icon_lshtm: As part of #WorldCancerDay, ICON and @LSHTM_CGCC will be hosting a hybrid film screening and Q&A on Thursday 8 February.….
0
5
0
RT @MJTSmith: 🚨 New #SystematicReview in @AnnalsOfEpi with @rachaelvp, @watzilei, @camaringe 🎉. How has Targeted Maximum Likelihood Estimat….
0
4
0
Sun setting on 2 days organised by the @royalsociety, joining the #PairingScheme23: listened to top-notch speakers on policy & science & media, how parliament and government work & role of the Government Office for Science! Met inspiring scientists and civil servants!
0
1
14
RT @RodZepeda: You want to know more about the connection between the #influencefunction and the #Deltamethod ? Check out our #preprint we….
0
5
0
RT @MJTSmith: If you’ve considered using Targeted Maximum Likelihood Estimation in the past for an observational study and decided not to u….
0
8
0
Expending the conversation on Immortal-Time bias! Thanks @SPilleron.
👋🏻 Self-promotion here 😀. Just posted on @medrxivpreprint our last paper on #ImmortalTimeBias in older vs younger age groups. Amazing work with @LeyClem, @camaringe and @EJAMorris . Ready for your comments 👇🏻👇🏻👇🏻.
1
0
8
Further evidence of the impact of covid-19 on cancer patients. Happy to have contributed to this research and see wider application of our survival models using population-based cancer registrations! Thanks @AggarwalOnc, @icon_lshtm!.
Our results demonstrate the sobering human and economic impacts of cancer diagnostic delay during the pandemic. Resolving this doesn’t require a sticking plaster but a strategic health systems approach to managing and coordinating complex cancer care. Paper 👇.
0
2
5
RT @SPilleron: 👋🏻 Our new paper #openaccess is out in @JGeriOnc .with @DiSarfati @EJAMorris @camaringe J. Atkinson and H. Charvat!. The imp….
0
6
0
RT @icon_lshtm: Be quick! Starting now is a live webinar by Prof Julian Peto and Dr Clare Gilham on “Breast cancer risk is reduced by early….
0
1
0
RT @icon_lshtm: We are recruiting! 👋 Are you an epidemiologist with strong quantitative skills, experienced and interested in improving #ca….
0
12
0
Check this out! And do send comments before we submit in January! Hopefully of use to many!.
New Paper! Tutorial: Introduction to computational causal inference using reproducible Stata, R and Python code @WATZILEI @camaringe @PausalZ @CausalInferBot @epi_twit @statstwitbot #epitwitter #tmle #stats #causalinference
1
0
10
RT @icon_lshtm: Measurements of deprivation are very important for research on health #inequalities, but do area-level scores and personal….
0
3
0
RT @NCRI_partners: Are you a #cancer patient or carer who wants to get involved in #cancerresearch? Join us on Thursday at our free #NCRIVi….
0
8
0
Further evidence that #Cancer shouldn't be forgotten in 2020! Timely access to treatment is paramount!.
We estimate for each 4 week delay in cancer treatment around a 10% increase in the risk of death. Meta-analysis of 7 cancers. We must continue cancer treatments during the 2nd #COVID19 wave or face a significant rise in avoidable cancer deaths.
0
1
5
Really looking forward to this closing session of the #NCRIVirtual. Prof. Sir Mike Richards always has pearls of wisdom to share!.
The #NCRIVirtual Showcase closing session starts in 5 mins: 'In conversation with… Mike Richards'. One not to miss! 👨🏫.
0
0
4
RT @DrN_CancerPCP: Cancer is STILL not going away and neither is COVID-19. As cases unfortunately continue to rise, it is important that we….
0
13
0
RT @f2harrell: Outstanding new tutorial on survival analysis: (just wish it weren't paywalled) #rmscourse.
0
125
0
14/14 The paper discusses model-averaging in low-resolution and high-resolution settings, with few and many cohorts, for cancer with high and low 5-year survival.
1
0
2